Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat
Friedrich N, Németh K, Tanner M, Rosta J, Dobos I, Oszlács O, Jancsó G, Meßlinger K, Dux M (2024)
Publication Type: Journal article
Publication year: 2024
Journal
Book Volume: 25
Article Number: 9
Journal Issue: 1
DOI: 10.1186/s10194-024-01717-2
Abstract
Background: Monoclonal antibodies directed against the neuropeptide calcitonin gene-related peptide (CGRP) are effective in the prevention of chronic and frequent episodic migraine. Since the antibodies do not cross the blood brain barrier, their antinociceptive effect is attributed to effects in meningeal tissues. We aimed to probe if such an antibody can be visualized within the dura mater and the trigeminal ganglia following its administration to rats and to examine if the activity of the trigeminovascular nocisensor complex is influenced by this treatment. Methods: Effects of the anti-CGRP antibody galcanezumab on the trigeminovascular nocisensor complex was examined by measuring release of sensory neuropeptides and histamine from the rat dura mater. Deposits of galcanezumab were visualized by fluorescence microscopy in the trigeminal ganglion and the dura mater. Results: Fluorophore-labelled galcanezumab was detected in the dura mater and the trigeminal ganglion up to 30 days after treatment affirming the long-lasting modulatory effect of this antibody. In female rats, seven days after systemic treatment with galcanezumab the capsaicin-induced release of CGRP was decreased, while that of substance P (SP) was increased in the dura mater. In control rats, release of the inhibitory neuropeptide somatostatin (SOM) was higher in females than in males. Stimulation with high concentration of KCl did not significantly change the release of SOM in control animals, while in rats treated with galcanezumab SOM release was slightly reduced. Galcanezumab treatment also reduced the amount of histamine released from dural mast cells upon stimulation with CGRP, while the effect of compound 48/80 on histamine release was not changed. Conclusions: Galcanezumab treatment is followed by multiple changes in the release of neuropeptides and histamine in the trigeminal nocisensor complex, which may contribute to the migraine preventing effect of anti-CGRP antibodies. These changes affecting the communication between the components of the trigeminal nocisensor complex may reduce pain susceptibility in migraine patients treated with CGRP targeting monoclonal antibodies.
Authors with CRIS profile
Involved external institutions
University of Szeged / József Attila Tudományegyetem Szeged
Hungary (HU)
MTA Research Centre for Natural Sciences (MTA TTK, RCNS), Chemical Research Center of the Hungarian Academy of Sciences / Magyar Tudományos Akadémia Kémiai Kutatóközpont
Hungary (HU)
Hungary (HU)
MTA Research Centre for Natural Sciences (MTA TTK, RCNS), Chemical Research Center of the Hungarian Academy of Sciences / Magyar Tudományos Akadémia Kémiai Kutatóközpont
Hungary (HU)
How to cite
APA:
Friedrich, N., Németh, K., Tanner, M., Rosta, J., Dobos, I., Oszlács, O.,... Dux, M. (2024). Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat. Journal of Headache and Pain, 25(1). https://doi.org/10.1186/s10194-024-01717-2
MLA:
Friedrich, Nadine, et al. "Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat." Journal of Headache and Pain 25.1 (2024).
BibTeX: Download